Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis
| Condition | Non Alcoholic Steatohepatitis, Fibrosis |
|---|---|
| Phase | Phase 1/2 |
| Sponsor | Stanford University |
| Status | Completed |
| Enrollment | 53 participants |
| Interventions | Idebenone |
| Start date | Jul 30, 2021 |
| Completion date | Jul 5, 2023 |
| Results posted | Mar 27, 2026 |
Summary
This is a randomized, placebo-controlled phase 1/2a study to investigate the safety and tolerability of Idebenone in patients 18 years of age or older with non-alcoholic steatohepatitis, with stage 1-3 fibrosis. As secondary end point target engagement and fibrosis improvement will be assessed.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0
| Idebenone | 9 Participants |
|---|---|
| Placebo | 4 Participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatoh — Akero Therapeutics, Inc
- Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
- Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
- Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
- Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.